Clas- III β-tubulin in normal and cancer tissues

Gene

Volumn 563, Issue 2, 2015, Pages 109-114

  Mariani, Marisa ^a   Karki, Roshan ^a   Spennato, Manuela ^a   Pandya, Deep ^a   He, Shiquan ^a   Andreoli, Mirko ^a   Fiedler, Paul ^a   Ferlini, Cristiano ^a  

^a DANBURY HOSPITAL   (United States)

Author keywords

Biomarker; Cancer; Neural differentiation; TUBB3; III Tubulin

Indexed keywords

BETA 3 TUBULIN; BETA TUBULIN; BIOLOGICAL MARKER; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG; TUBULIN;

CANCER PATIENT; CANCER TISSUE; DRUG RESISTANCE; DRUG TARGETING; GENE; GENE STRUCTURE; HUMAN; HUMAN TISSUE; MICROTUBULE; NERVE CELL DIFFERENTIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUBB3 GENE; ANIMAL; METABOLISM; NEOPLASM; NEURAL CREST;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; MICROTUBULES; NEOPLASMS; NEURAL CREST; TUBULIN;

EID: 84927100883     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.03.061     Document Type: Review

References (91)

1. Akasaka K., Maesawa C., Shibazaki M., Maeda F., Takahashi K., Akasaka T., Masuda T. Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J. Invest. Dermatol. 2009, 129(6):1516-1526.
2. Andre N., Braguer D., Brasseur G., Goncalves A., Lemesle-Meunier D., Guise S., Jordan M.A., Briand C. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res. 2000, 60(19):5349-5353.
3. Andreoli M., Persico M., Kumar A., Orteca N., Kumar V., Pepe A., Mahalingam S., Alegria A.E., Petrella L., Sevciunaite L., et al. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J. Med. Chem. 2014, 57(19):7916-7932.
4. Aoki D., Oda Y., Hattori S., Taguchi K., Ohishi Y., Basaki Y., Oie S., Suzuki N., Kono S., Tsuneyoshi M., et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin. Cancer Res. 2009, 15(4):1473-1480.
5. Azuma K., Sasada T., Kawahara A., Takamori S., Hattori S., Ikeda J., Itoh K., Yamada A., Kage M., Kuwano M., et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64(3):326-333.
6. Barford D. The role of cysteine residues as redox-sensitive regulatory switches. Curr. Opin. Struct. Biol. 2004, 14(6):679-686.
7. Caccamo D., Katsetos C.D., Herman M.M., Frankfurter A., Collins V.P., Rubinstein L.J. Immunohistochemistry of a spontaneous murine ovarian teratoma with neuroepithelial differentiation. Neuron-associated beta-tubulin as a marker for primitive neuroepithelium. Lab. Investig. 1989, 60(3):390-398.
8. Cai P., Lu P., Sharom F.J., Fang W.S. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and beta-III tubulin mediated tumor drug resistance in vitro. Cancer Lett. 2013, 341(2):214-223.
9. Caracciolo V., D'Agostino L., Draberova E., Sladkova V., Crozier-Fitzgerald C., Agamanolis D.P., de Chadarevian J.P., Legido A., Giordano A., Draber P., et al. Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines. J. Cell. Physiol. 2010, 223(2):519-529.
10. Carrara L., Guzzo F., Roque D.M., Bellone S., Emiliano C., Sartori E., Pecorelli S., Schwartz P.E., Rutherford T.J., Santin A.D. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecol. Oncol. 2012, 125(1):231-236.
11. Cicchillitti L., Penci R., Di Michele M., Filippetti F., Rotilio D., Donati M.B., Scambia G., Ferlini C. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol. Cancer Ther. 2008, 7(7):2070-2079.
12. Colombo N., Kutarska E., Dimopoulos M., Bae D.S., Rzepka-Gorska I., Bidzinski M., Scambia G., Engelholm S.A., Joly F., Weber D., et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J. Clin. Oncol. 2012, 30(31):3841-3847.
13. Cortese F., Bhattacharyya B., Wolff J. Podophyllotoxin as a probe for the colchicine binding site of tubulin. J. Biol. Chem. 1977, 252(4):1134-1140.
14. De Donato M., Mariani M., Petrella L., Martinelli E., Zannoni G.F., Vellone V., Ferrandina G., Shahabi S., Scambia G., Ferlini C. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J. Cell. Physiol. 2012, 227(3):1034-1041.
15. De Gendt K., Denolet E., Willems A., Daniels V.W., Clinckemalie L., Denayer S., Wilkinson M.F., Claessens F., Swinnen J.V., Verhoeven G. Expression of Tubb3, a beta-tubulin isotype, is regulated by androgens in mouse and rat Sertoli cells. Biol. Reprod. 2011, 85(5):934-945.
16. Draberova E., Del Valle L., Gordon J., Markova V., Smejkalova B., Bertrand L., de Chadarevian J.P., Agamanolis D.P., Legido A., Khalili K., et al. Class III beta-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. J. Neuropathol. Exp. Neurol. 2008, 67(4):341-354.
17. Ferlini C., Raspaglio G., Mozzetti S., Cicchillitti L., Filippetti F., Gallo D., Fattorusso C., Campiani G., Scambia G. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res. 2005, 65(6):2397-2405.
18. Ferlini C., Raspaglio G., Cicchillitti L., Mozzetti S., Prislei S., Bartollino S., Scambia G. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?. Curr. Cancer Drug Targets 2007, 7(8):704-712.
19. Ferlini C., Cicchillitti L., Raspaglio G., Bartollino S., Cimitan S., Bertucci C., Mozzetti S., Gallo D., Persico M., Fattorusso C., et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009, 69(17):6906-6914.
20. Ferrandina G., Martinelli E., Zannoni G.F., Distefano M., Paglia A., Ferlini C., Scambia G. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol. Oncol. 2007, 104(2):326-330.
21. Ferrandina G., Mariani M., Andreoli M., Shahabi S., Scambia G., Ferlini C. Novel drugs targeting microtubules: the role of epothilones. Curr. Pharm. Des. 2012, 18(19):2793-2803.
22. Foudah D., Monfrini M., Donzelli E., Niada S., Brini A.T., Orciani M., Tredici G., Miloso M. Expression of neural markers by undifferentiated mesenchymal-like stem cells from different sources. J. Immunol. Res. 2014, 2014:987678.
23. Galmarini C.M., Treilleux I., Cardoso F., Bernard-Marty C., Durbecq V., Gancberg D., Bissery M.C., Paesmans M., Larsimont D., Piccart M.J., et al. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin. Cancer Res. 2008, 14(14):4511-4516.
24. Gan P.P., Pasquier E., Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 2007, 67(19):9356-9363.
25. Gao S., Zhao X., Lin B., Hu Z., Yan L., Gao J. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance. Tumour Biol. 2012, 33(5):1759-1765.
26. Hari M., Yang H., Zeng C., Canizales M., Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil. Cytoskeleton 2003, 56(1):45-56.
27. Hayashi Y., Kuriyama H., Umezu H., Tanaka J., Yoshimasu T., Furukawa T., Tanaka H., Kagamu H., Gejyo F., Yoshizawa H. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern. Med. 2009, 48(4):203-208.
28. Hirai Y., Yoshimasu T., Oura S., Ota F., Naito K., Nishiguchi H., Hashimoto S., Okamura Y. Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence. Anticancer Res. 2011, 31(3):999-1005.
29. Ishida M., Kushima R., Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol. Rep. 2009, 22(4):733-737.
30. Joe P.A., Banerjee A., Luduena R.F. The roles of cys124 and ser239 in the functional properties of human betaIII tubulin. Cell Motil. Cytoskeleton 2008, 65(6):476-486.
31. Jordan M.A., Kamath K. How do microtubule-targeted drugs work? An overview. Curr. Cancer Drug Targets 2007, 7(8):730-742.
32. Karki R., Mariani M., Andreoli M., He S., Scambia G., Shahabi S., Ferlini C. betaIII-Tubulin: biomarker of taxane resistance or drug target?. Expert Opin. Ther. Targets 2013, 17(4):461-472.
33. Katsetos C.D., Draber P. Tubulins as therapeutic targets in cancer: from bench to bedside. Curr. Pharm. Des. 2012, 18(19):2778-2792.
34. Katsetos C.D., Del Valle L., Geddes J.F., Assimakopoulou M., Legido A., Boyd J.C., Balin B., Parikh N.A., Maraziotis T., de Chadarevian J.P., et al. Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch. Pathol. Lab. Med. 2001, 125(5):613-624.
35. Katsetos C.D., Herman M.M., Mork S.J. Class III beta-tubulin in human development and cancer. Cell Motil. Cytoskeleton 2003, 55(2):77-96.
36. Katsetos C.D., Legido A., Perentes E., Mork S.J. Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J. Child Neurol. 2003, 18(12):851-866. (discussion 867).
37. Katsetos C.D., Draberova E., Smejkalova B., Reddy G., Bertrand L., de Chadarevian J.P., Legido A., Nissanov J., Baas P.W., Draber P. Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem. Res. 2007, 32(8):1387-1398.
38. Katsetos C.D., Draberova E., Legido A., Draber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin. J. Cell. Physiol. 2009, 221(3):514-520.
39. Katsetos C.D., Draber P., Kavallaris M. Targeting betaIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anti Cancer Agents Med. Chem. 2011, 11(8):719-728.
40. Kavallaris M., Kuo D.Y., Burkhart C.A., Regl D.L., Norris M.D., Haber M., Horwitz S.B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 1997, 100(5):1282-1293.
41. Khan I.A., Luduena R.F. Possible regulation of the in vitro assembly of bovine brain tubulin by the bovine thioredoxin system. Biochim. Biophys. Acta 1991, 1076(2):289-297.
42. Koh Y., Jang B., Han S.W., Kim T.M., Oh D.Y., Lee S.H., Kang C.H., Kim D.W., Im S.A., Chung D.H., et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J. Thorac. Oncol. 2010, 5(3):320-325.
43. Lee M.K., Tuttle J.B., Rebhun L.I., Cleveland D.W., Frankfurter A. The expression and posttranslational modification of a neuron-specific beta-tubulin isotype during chick embryogenesis. Cell Motil. Cytoskeleton 1990, 17(2):118-132.
44. Leskela S., Leandro-Garcia L.J., Mendiola M., Barriuso J., Inglada-Perez L., Munoz I., Martinez-Delgado B., Redondo A., de Santiago J., Robledo M., et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr. Relat. Cancer 2011, 18(1):85-95.
45. Levallet G., Bergot E., Antoine M., Creveuil C., Santos A.O., Beau-Faller M., de Fraipont F., Brambilla E., Levallet J., Morin F., et al. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol. Cancer Ther. 2012, 11(5):1203-1213.
46. Li W., Zhai B., Zhi H., Li Y., Jia L., Ding C., Zhang B., You W. Association of ABCB1, beta tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7. Tumour Biol. 2014, 35(9):8883-8891.
47. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., Dawson M.I., Reed J.C., Zhang X.K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116(4):527-540.
48. Linhartova I., Draber P., Draberova E., Viklicky V. Immunological discrimination of beta-tubulin isoforms in developing mouse brain. Post-translational modification of non-class-III beta-tubulins. Biochem. J. 1992, 288(Pt 3):919-924.
49. Loike J.D., Horwitz S.B. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 1976, 15(25):5435-5443.
50. Magnani M., Ortuso F., Soro S., Alcaro S., Tramontano A., Botta M. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J. 2006, 273(14):3301-3310.
51. Mariani M., Zannoni G.F., Sioletic S., Sieber S., Martino C., Martinelli E., Coco C., Scambia G., Shahabi S., Ferlini C. Gender influences the Class III and V beta-tubulin ability to predict poor outcome in colorectal cancer. Clin. Cancer Res. 2012, 18(10):2964-2975.
52. McCarroll J.A., Gan P.P., Liu M., Kavallaris M. betaIII-Tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res. 2010, 70(12):4995-5003.
53. McCarroll J.A., Gan P.P., Erlich R.B., Liu M., Dwarte T., Sagnella S., Akerfeldt M., Yang L., Parker A.L., Chang M.H., et al. TUBB3/betaIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res. 2015, 75(2):415-425.
54. Miyamoto A., Akasaka K., Oikawa H., Akasaka T., Masuda T., Maesawa C. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease. Am. J. Dermatopathol. 2010, 32(6):578-585.
55. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 2011, 89(4):491-502.
56. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., Gallo D., Martinelli E., Ranelletti F.O., Ferrandina G., et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 2005, 11(1):298-305.
57. Mozzetti S., Iantomasi R., De Maria I., Prislei S., Mariani M., Camperchioli A., Bartollino S., Gallo D., Scambia G., Ferlini C. Molecular mechanisms of patupilone resistance. Cancer Res. 2008, 68(24):10197-10204.
58. Ohishi Y., Oda Y., Basaki Y., Kobayashi H., Wake N., Kuwano M., Tsuneyoshi M. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol. Oncol. 2007, 105(3):586-592.
59. Orsted D.D., Nordestgaard B.G., Bojesen S.E. Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study. Ann. Oncol. 2014, 25(3):712-718.
60. Panda D., Miller H.P., Banerjee A., Luduena R.F., Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(24):11358-11362.
61. Pepe A., Sun L., Zanardi I., Wu X., Ferlini C., Fontana G., Bombardelli E., Ojima I. Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin. Bioorg. Med. Chem. Lett. 2009, 19(12):3300-3304.
62. Persico M., Petrella L., Orteca N., Di Dato A., Mariani M., Andreoli M., De Donato M., Scambia G., Novellino E., Ferlini C., et al. GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1. Eur. J. Med. Chem. 2015, 91:132-144.
63. Petschnik A.E., Fell B., Tiede S., Habermann J.K., Pries R., Kruse C., Danner S. A novel xenogeneic co-culture system to examine neuronal differentiation capability of various adult human stem cells. PLoS One 2011, 6(9):e24944.
64. Ploussard G., Terry S., Maille P., Allory Y., Sirab N., Kheuang L., Soyeux P., Nicolaiew N., Coppolani E., Paule B., et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 2010, 70(22):9253-9264.
65. Poirier K., Saillour Y., Bahi-Buisson N., Jaglin X.H., Fallet-Bianco C., Nabbout R., Castelnau-Ptakhine L., Roubertie A., Attie-Bitach T., Desguerre I., et al. Mutations in the neuronal ss-tubulin subunit TUBB3 result in malformation of cortical development and neuronal migration defects. Hum. Mol. Genet. 2010, 19(22):4462-4473.
66. Prislei S., Mozzetti S., Filippetti F., De Donato M., Raspaglio G., Cicchillitti L., Scambia G., Ferlini C. From plasma membrane to cytoskeleton: a novel function for semaphorin 6A. Mol. Cancer Ther. 2008, 7(1):233-241.
67. Prislei S., Martinelli E., Mariani M., Raspaglio G., Sieber S., Ferrandina G., Shahabi S., Scambia G., Ferlini C. MiR-200c and HuR in ovarian cancer. BMC Cancer 2013, 13:72.
68. Raspaglio G., Ferrandina G., Ferlini C., Scambia G., Ranelletti F.O. Epidermal growth factor-responsive laryngeal squamous cancer cell line Hep2 is more sensitive than unresponsive CO-K3 one to quercetin and tamoxifen apoptotic effects. Oncol. Res. 2003, 14(2):83-91.
69. Raspaglio G., Filippetti F., Prislei S., Penci R., De Maria I., Cicchillitti L., Mozzetti S., Scambia G., Ferlini C. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 2008, 409(1-2):100-108.
70. Raspaglio G., De Maria I., Filippetti F., Martinelli E., Zannoni G.F., Prislei S., Ferrandina G., Shahabi S., Scambia G., Ferlini C. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res. 2010, 70(14):5891-5900.
71. Raspaglio G., Petrillo M., Martinelli E., Li Puma D.D., Mariani M., De Donato M., Filippetti F., Mozzetti S., Prislei S., Zannoni G.F., et al. Sox9 and Hif-2alpha regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene 2014, 542(2):173-181.
72. Reiman T., Lai R., Veillard A.S., Paris E., Soria J.C., Rosell R., Taron M., Graziano S., Kratzke R., Seymour L., et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann. Oncol. 2012, 23(1):86-93.
73. Roque D.M., Buza N., Glasgow M., Bellone S., Bortolomai I., Gasparrini S., Cocco E., Ratner E., Silasi D.A., Azodi M., et al. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin. Exp. Metastasis 2014, 31(1):101-110.
74. Saillour Y., Broix L., Bruel-Jungerman E., Lebrun N., Muraca G., Rucci J., Poirier K., Belvindrah R., Francis F., Chelly J. Beta tubulin isoforms are not interchangeable for rescuing impaired radial migration due to Tubb3 knockdown. Hum. Mol. Genet. 2014, 23(6):1516-1526.
75. Saussede-Aim J., Matera E.L., Ferlini C., Dumontet C. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil. Cytoskeleton 2009, 66(7):378-388.
76. Seve P., Isaac S., Tredan O., Souquet P.J., Pacheco Y., Perol M., Lafanechere L., Penet A., Peiller E.L., Dumontet C. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res. 2005, 11(15):5481-5486.
77. Seve P., Lai R., Ding K., Winton T., Butts C., Mackey J., Dumontet C., Dabbagh L., Aviel-Ronen S., Seymour L., et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin. Cancer Res. 2007, 13(3):994-999.
78. Shahabi S., He S., Kopf M., Mariani M., Petrini J., Scambia G., Ferlini C. Free testosterone drives cancer aggressiveness: evidence from US population studies. PLoS One 2013, 8(4):e61955.
79. Shibazaki M., Maesawa C., Akasaka K., Kasai S., Yasuhira S., Kanno K., Nakayama I., Sugiyama T., Wakabayasi G., Masuda T., et al. Transcriptional and post-transcriptional regulation of betaIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells. Int. J. Oncol. 2012, 40(3):695-702.
80. Sullivan K.F., Cleveland D.W. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc. Natl. Acad. Sci. U. S. A. 1986, 83(12):4327-4331.
81. Terry S., Ploussard G., Allory Y., Nicolaiew N., Boissiere-Michot F., Maille P., Kheuang L., Coppolani E., Ali A., Bibeau F., et al. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br. J. Cancer 2009, 101(6):951-956.
82. Tischfield M.A., Baris H.N., Wu C., Rudolph G., Van Maldergem L., He W., Chan W.M., Andrews C., Demer J.L., Robertson R.L., et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010, 140(1):74-87.
83. Towe K.M. Oxygen-collagen priority and the early metazoan fossil record. Proc. Natl. Acad. Sci. U. S. A. 1970, 65(4):781-788.
84. Tsourlakis M.C., Weigand P., Grupp K., Kluth M., Steurer S., Schlomm T., Graefen M., Huland H., Salomon G., Steuber T., et al. betaIII-Tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am. J. Pathol. 2014, 184(3):609-617.
85. Tuszynski J.A., Carpenter E.J., Huzil J.T., Malinski W., Luchko T., Luduena R.F. The evolution of the structure of tubulin and its potential consequences for the role and function of microtubules in cells and embryos. Int. J. Dev. Biol. 2006, 50(2-3):341-358.
86. Umezu T., Shibata K., Kajiyama H., Terauchi M., Ino K., Nawa A., Kikkawa F. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int. J. Gynecol. Pathol. 2008, 27(2):207-212.
87. Urano N., Fujiwara Y., Doki Y., Kim S.J., Miyoshi Y., Noguchi S., Miyata H., Takiguchi S., Yasuda T., Yano M., et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int. J. Oncol. 2006, 28(2):375-381.
88. Vilmar A., Garcia-Foncillas J., Huarriz M., Santoni-Rugiu E., Sorensen J.B. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 2012, 75(3):306-312.
89. Wang Y., Sparano J.A., Fineberg S., Stead L., Sunkara J., Horwitz S.B., McDaid H.M. High expression of class III beta-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. Clin. Breast Cancer 2013, 13(2):103-108.
90. Yoon S.O., Kim W.Y., Go H., Paik J.H., Kim J.E., Kim Y.A., Huh J.R., Jeon Y.K., Kim C.W. Class III beta-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders. Am. J. Surg. Pathol. 2010, 34(5):645-655.
91. Zhang H.L., Ruan L., Zheng L.M., Whyte D., Tzeng C.M., Zhou X.W. Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 2012, 77(1):9-15.